+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Inotek Pharma - logo

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. It is focused on the development and commercialization of therapies for glaucoma and other serious diseases of the eye. The company's lead product candidate is Trabodenoson, formerly known as INO-8875, which is in Phase III clinical trials for lowering IOP. Trabodenoson has completed Phase 1, 2, and 3 clinical trials in subjects with OHT and POAG. Inotek was founded in 1999.

Global Open-Angle Glaucoma Therapeutics Market 2023-2027 - Product Thumbnail Image

Global Open-Angle Glaucoma Therapeutics Market 2023-2027

  • Report
  • September 2023
  • 161 Pages
  • Global
From
From
Optic Nerve Disorders Treatment Global Market Report 2024 - Product Thumbnail Image

Optic Nerve Disorders Treatment Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
From
Adenosine A1 Receptor Agonist - Pipeline Insight, 2022 - Product Thumbnail Image

Adenosine A1 Receptor Agonist - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Adenosine A2A Receptor Agonist - Pipeline Insight, 2022 - Product Thumbnail Image

Adenosine A2A Receptor Agonist - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Adenosine A3 Receptor Agonist - Pipeline Insight, 2022 - Product Thumbnail Image

Adenosine A3 Receptor Agonist - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
Adenosine A1 Receptor Antagonist - Pipeline Insight, 2022 - Product Thumbnail Image

Adenosine A1 Receptor Antagonist - Pipeline Insight, 2022

  • Clinical Trials
  • January 2022
  • 60 Pages
  • Global
From
  • 13 Results (Page 1 of 1)
Loading Indicator